S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
NASDAQ:SYRS

Syros Pharmaceuticals - SYRS Stock Forecast, Price & News

$5.32
+0.21 (+4.11%)
(As of 02/1/2023 12:00 AM ET)
Add
Compare
Today's Range
$5.05
$5.67
50-Day Range
$3.03
$5.32
52-Week Range
$3.02
$21.00
Volume
221,474 shs
Average Volume
139,377 shs
Market Capitalization
$107.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.75

Syros Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
542.9% Upside
$34.20 Price Target
Short Interest
Healthy
3.65% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.89
Upright™ Environmental Score
News Sentiment
1.07mentions of Syros Pharmaceuticals in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($9.19) to ($5.16) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.72 out of 5 stars

Medical Sector

74th out of 1,053 stocks

Pharmaceutical Preparations Industry

24th out of 519 stocks


SYRS stock logo

About Syros Pharmaceuticals (NASDAQ:SYRS) Stock

Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.

Receive SYRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SYRS Stock News Headlines

Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
SYRS Syros Pharmaceuticals, Inc.
Analyst Expectations for Syros Pharmaceuticals's Future
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
See More Headlines
Receive SYRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SYRS Company Calendar

Last Earnings
11/14/2022
Today
2/02/2023
Next Earnings (Estimated)
3/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SYRS
Fax
N/A
Employees
124
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$34.20
High Stock Price Forecast
$100.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+233.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-86,560,000.00
Net Margins
-485.12%
Pretax Margin
-485.12%

Debt

Sales & Book Value

Annual Sales
$23.49 million
Book Value
$13.76 per share

Miscellaneous

Free Float
17,639,000
Market Cap
$107.62 million
Optionable
Optionable
Beta
1.56

Key Executives

  • Nancy A. Simonian
    President, Chief Executive Officer & Director
  • Jason Haas
    Chief Financial Officer
  • Eric R. OlsonEric R. Olson
    Chief Scientific Officer
  • David A. Roth
    Chief Medical Officer
  • Conley Chee
    Chief Commercial Officer













SYRS Stock - Frequently Asked Questions

Should I buy or sell Syros Pharmaceuticals stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SYRS shares.
View SYRS analyst ratings
or view top-rated stocks.

What is Syros Pharmaceuticals' stock price forecast for 2023?

5 equities research analysts have issued 12 month price objectives for Syros Pharmaceuticals' shares. Their SYRS share price forecasts range from $15.00 to $100.00. On average, they expect the company's share price to reach $34.20 in the next twelve months. This suggests a possible upside of 542.9% from the stock's current price.
View analysts price targets for SYRS
or view top-rated stocks among Wall Street analysts.

How have SYRS shares performed in 2023?

Syros Pharmaceuticals' stock was trading at $3.59 at the beginning of the year. Since then, SYRS stock has increased by 48.2% and is now trading at $5.32.
View the best growth stocks for 2023 here
.

Are investors shorting Syros Pharmaceuticals?

Syros Pharmaceuticals saw a decrease in short interest during the month of January. As of January 15th, there was short interest totaling 584,700 shares, a decrease of 39.4% from the December 31st total of 964,400 shares. Based on an average daily volume of 108,000 shares, the days-to-cover ratio is currently 5.4 days. Approximately 3.7% of the company's stock are sold short.
View Syros Pharmaceuticals' Short Interest
.

When is Syros Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 21st 2023.
View our SYRS earnings forecast
.

How were Syros Pharmaceuticals' earnings last quarter?

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) issued its earnings results on Monday, November, 14th. The company reported ($2.41) earnings per share for the quarter, topping the consensus estimate of ($3.91) by $1.50. The firm had revenue of $3.89 million for the quarter, compared to the consensus estimate of $4.97 million. Syros Pharmaceuticals had a negative trailing twelve-month return on equity of 141.16% and a negative net margin of 485.12%.

When did Syros Pharmaceuticals' stock split?

Syros Pharmaceuticals's stock reverse split on Monday, September 19th 2022. The 1-10 reverse split was announced on Monday, September 19th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Nancy Simonian's approval rating as Syros Pharmaceuticals' CEO?

3 employees have rated Syros Pharmaceuticals Chief Executive Officer Nancy Simonian on Glassdoor.com. Nancy Simonian has an approval rating of 100% among the company's employees. This puts Nancy Simonian in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Syros Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), ImmunoGen (IMGN), VBI Vaccines (VBIV), Amarin (AMRN), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR) and Pfizer (PFE).

When did Syros Pharmaceuticals IPO?

(SYRS) raised $60 million in an initial public offering on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Syros Pharmaceuticals' stock symbol?

Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."

Who are Syros Pharmaceuticals' major shareholders?

Syros Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Eric R Olson, Eric R Olson, Mark J Alles, Richard A Young, Srinivas Akkaraju and Timothy Tyson.
View institutional ownership trends
.

How do I buy shares of Syros Pharmaceuticals?

Shares of SYRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Syros Pharmaceuticals' stock price today?

One share of SYRS stock can currently be purchased for approximately $5.32.

How much money does Syros Pharmaceuticals make?

Syros Pharmaceuticals (NASDAQ:SYRS) has a market capitalization of $107.62 million and generates $23.49 million in revenue each year. The company earns $-86,560,000.00 in net income (profit) each year or ($16.41) on an earnings per share basis.

How many employees does Syros Pharmaceuticals have?

The company employs 124 workers across the globe.

How can I contact Syros Pharmaceuticals?

Syros Pharmaceuticals' mailing address is 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139. The official website for the company is www.syros.com. The company can be reached via phone at (617) 744-1340 or via email at hannahd@sternir.com.

This page (NASDAQ:SYRS) was last updated on 2/2/2023 by MarketBeat.com Staff